FDA is weighing how to encourage state officials to enter information-sharing agreements for drug compounding oversight after state stakeholders expressed concerns that some agency requirements, such as those that conflict with some state sunshine laws, pose major legal hurdles, according to
recently released minutes of an FDA meeting with state regulators and stakeholders.
No comments:
Post a Comment